Aerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to deliver RNA Medicines to the Brain.
PRIVATEFeb 09, 2026
Amount Raised
$39 Million
Round Type
Series A
DublinBiotechnologyHealth CareMedicalTherapeutics
Investors
Iaso VenturesEQT Dementia FundAge1
Description
Aerska, a biotechnology company, announced the close of a $39 million Series A financing led by EQT Dementia Fund and age1. The funding will be used to advance its brain shuttle technology for treating neurological diseases. This brings total funds raised to $60 million. Aerska's platform aims for effective RNAi therapeutics delivery across the blood-brain barrier.
Company Information
Company
Aerska
Location
Dublin, Dublin, Ireland
About
Aerska is a biotechnology company developing RNA medicines to treat, delay, and prevent diseases of the brain. The company is leveraging advances in ‘brain shuttles’ to enable targeted delivery of next-generation RNAi therapeutics to the CNS. Aerska is headquartered in Dublin, Ireland, with research operations in London, UK.
Fundz sees it the moment Aerska raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
DublinBiotechnologyHealth CareMedicalTherapeutics